Zhejiang Xianju Pharmaceutical Co.,Ltd.: history, ownership, mission, how it works & makes money

Founded in 1972 as Xianju Pharmaceutical Factory and listed on the Shenzhen Stock Exchange in 2010 under 002332.SZ, Zhejiang Xianju Pharmaceutical has grown into a top-100 Chinese pharma and a key high-tech enterprise in the National Torch Program, employing 3,205 people as of December 31, 2024 and managing a total share capital of 989,204,866 yuan; the company combines two standardized API plants and three production platforms to supply corticosteroids, sex hormones, anesthetics, muscle relaxants and respiratory drugs, reported revenue of 4.00 billion yuan in 2024 (down 2.98% year-on-year) and operating revenue of 2.826 billion yuan in the first three quarters of 2025 (down 12.71%) while holding a 37.3879% stake in Zhejiang Cuize Pharmaceutical as of June 2025 and electing to forgo priority subscription rights in a Cuize capital increase; strategic R&D ties with over 20 domestic institutes, NMPA approval for estradiol valerate tablets in July 2024, clinical trial clearance for Roflumilast Foam in June 2025, and analyst forecasts-earnings growth of 24.2% and revenue growth of 11.7% per annum (EPS +24.3%)-frame a company balancing near-term procurement pressures and a market capitalization of approximately 9.47 billion yuan as of November 7, 2025

Zhejiang Xianju Pharmaceutical Co.,Ltd. (002332.SZ): Intro

• Founded: 1972 (Xianju Pharmaceutical Factory)
• Headquarters: Xianju County, Taizhou City, Zhejiang Province, China
• Listing: Shenzhen Stock Exchange, 2010 - ticker 002332.SZ
• Employees: 3,205 (as of December 31, 2024)

History & Development

Originating as a county-level pharmaceutical factory in 1972, the company evolved through modernization and capacity expansion into a listed drug manufacturer by 2010. Over decades it broadened operations from basic APIs to finished formulations and established collaborations with major domestic research institutes to boost R&D and product pipeline development.

Core Product Portfolio

• Corticosteroids
• Sex hormones (including estradiol valerate tablets registered July 2024)
• Anesthetics
• Muscle relaxants
• Respiratory drugs

R&D and Partnerships

To strengthen innovation and scale, Zhejiang Xianju Pharmaceutical maintains long-term cooperative relationships with over 20 domestic research institutes and universities. Notable partners include:

• Shanghai Institute of Organic Chemistry
• Zhejiang University
• Multiple provincial research centers and clinical collaborators

How It Operates

Operationally, the company integrates API synthesis, formulation manufacturing, quality control, and regulatory affairs across production sites. Key operational elements include:

• API R&D and manufacturing for steroidal and small-molecule drugs
• Formulation development and scale-up for oral tablets, injectables
• Regulatory submissions and NMPA compliance (recent approval: estradiol valerate tablets)
• Sales through hospital procurement, distributors, and institutional tenders

Business Model & Revenue Streams

Primary revenue drivers and value-creation activities:

• Manufacture and sale of proprietary and generic finished-dose pharmaceuticals to hospitals and distributors
• Production and sale of APIs to domestic and contract-manufacturing partners
• R&D-driven new product approvals and line extensions (e.g., hormonal therapies)
• Contract manufacturing and technical cooperation with research institutes and pharma companies

Ownership & Corporate Structure

As a publicly listed company (002332.SZ), ownership is distributed among institutional investors, retail shareholders, and the company's controlling stakeholders as disclosed in regulatory filings. Corporate governance follows Shenzhen Stock Exchange disclosure requirements, with reported board and management structures in annual reports.

Further reading and profile: Zhejiang Xianju Pharmaceutical Co.,Ltd.: History, Ownership, Mission, How It Works & Makes Money

Zhejiang Xianju Pharmaceutical Co.,Ltd. (002332.SZ): History

• Listing: Shenzhen Stock Exchange, ticker 002332.SZ.
• Total share capital: 989,204,866 yuan (registered capital).
• Market capitalization: ~9.47 billion yuan (as of 2025-11-07).
• Affiliated holdings: 37.3879% stake in Zhejiang Cuize Pharmaceutical Technology Co., Ltd. (as of June 2025).
• June 2025 corporate action: relinquished priority subscription rights for a capital increase in Cuize Pharmaceutical to adjust investment exposure.
• Investor base: mix of domestic and international institutional and individual investors supporting financial stability and growth.

• How ownership shapes strategy: significant minority holding in Cuize tied to collaborative R&D and production synergies; relinquishment of subscription rights signals portfolio rebalancing.
• Capital and investor mix: nearly 1.0 billion yuan share capital and diversified holders (institutional & individual, domestic & international) underpin access to capital markets and M&A flexibility.

Zhejiang Xianju Pharmaceutical Co.,Ltd. (002332.SZ): Ownership Structure

• Mission: 'Our sincerity and responsibility for your health and happiness' - driving product quality, safety, and patient outcomes.
• Vision: Become a top-ten global supplier of steroid drugs and a preferred employer and partner.
• Culture & Values: Truthfulness, win-win, innovation; integrity, struggle, openness, learning, responsibility, win-win.
• Technology & Innovation: Recognized under the National Torch Program; sustained R&D investments to support steroid and API pipelines.

• Zhejiang Xianju Group / Related strategic investor - 25.12%
• Founders / Management & affiliated entities - 12.50%
• Institutional & public investors (free float) - 45.00%
• Other strategic/investor holdings - 17.38%

• Product portfolio centered on steroid APIs, formulations, and specialty generics-commercialized through domestic hospitals, pharmacies, and export channels.
• Manufacturing and quality systems to meet GMP and exported-market standards; scale and cost advantages in steroid API production support gross margins.
• Continued R&D investment (≈4-5% of revenue) to develop new formulations, improve yields, and expand therapeutic indications.
• Sales channels: hospital tendering, distributor networks, and growing international exports-pricing and volume mix drive revenue variability.

Zhejiang Xianju Pharmaceutical Co.,Ltd. (002332.SZ): Mission and Values

• Three core manufacturing platforms: Xianju Yangfu API Production Area, Xianju Yangfu Preparation Production Area and Linhai Chuanlan Production Area - each optimized for different stages of API synthesis, formulation development and commercial packaging.
• Two standardized API plants supporting centralized raw-material chemistry, impurity control and scale-up to commercial volumes, minimizing tech-transfer friction into preparation lines.
• Integrated APIs + preparations model facilitating cost control, product lifecycle management and faster market launches by internalizing API sources for key formulations.
• Product and service clusters concentrated in gynecology, anesthesiology, respiratory and dermatology, allowing focused clinical development, regulatory filings and targeted commercial teams.

• Foreign high-end R&D institutions - source of cutting-edge leads, advanced synthetic routes and regulatory strategy inputs.
• Hangzhou and Xianju research institutes - digestion, optimization and localization of foreign-origin technologies; pilot development, formulation screening and stability work.
• Xianju production base - pilot-to-commercial implementation, scale-up, quality systems and GMP launch readiness.

• Projects under the National "863" Program (high-tech development).
• Projects under the National Torch Program (industrial technology and entrepreneurship).
• Projects under the National Major New Drug Development program (drug innovation and clinical translation).

• API sales: bulk active pharmaceutical ingredients sold to internal formulation lines and external customers - creates margin capture and supply security.
• Preparations / finished dosage forms: prescription and hospital-market formulations in the four therapeutic clusters driving higher value-per-unit sales.
• Contract manufacturing and technical service revenue: pilot-to-commercial tech transfer, custom synthesis and contract supply for partners.
• Licensing and collaborative R&D: out-licensing specialty compounds or co-development agreements originating from national program projects.

Zhejiang Xianju Pharmaceutical Co.,Ltd. (002332.SZ): How It Works

• Primary revenue streams: sale of steroid APIs, production and sale of finished steroid preparations, contract manufacturing for domestic and export clients, and licensing/registration-driven product launches.
• Product portfolio includes corticosteroid drugs, sex hormone drugs (including estradiol valerate), anesthetics, muscle relaxants, and respiratory drugs.
• Market access: domestic hospital and retail channels, provincial centralized procurement, and international export markets.

• API manufacturing scale: economies of scale in steroid API production lower unit costs and support domestic and export margins.
• Finished formulation sales: higher-margin branded or registered tablet/injectable preparations sold through hospital procurement and retail pharmacies.
• Policy sensitivity: revenues are influenced by provincial and national pharmaceutical procurement policies and price negotiations, which contributed to the 12.71% decline in revenue through Q3 2025.
• Regulatory expansion: new drug registrations expand addressable market - e.g., the company received a Drug Registration Certificate for estradiol valerate tablets in July 2024, enabling additional finished-product sales.
• Contract manufacturing and exports: third-party production and overseas sales supplement domestic revenues and utilize excess manufacturing capacity.

• Listed company structure (Shenzhen Stock Exchange: 002332.SZ) with a mix of institutional and retail shareholders.
• Competitive niche in steroid APIs and preparations, with market valuation reflected by a ~9.47 billion CNY market cap (2025-11-07).

• Product development and registration efforts (e.g., estradiol valerate tablets) indicate a strategy to broaden the finished-product pipeline and move up the value chain from APIs to higher-margin preparations.
• For corporate mission, vision and core values, see: Mission Statement, Vision, & Core Values (2026) of Zhejiang Xianju Pharmaceutical Co.,Ltd.

Zhejiang Xianju Pharmaceutical Co.,Ltd. (002332.SZ): How It Makes Money

• Core revenue from sales of finished drugs and APIs to hospitals, distributors and export markets.
• Contract manufacturing and OEM/ODM services for domestic and international pharmaceutical partners.
• Licensing and milestone payments from out-licensing of clinical-stage and approved formulations (including dermatology assets).
• R&D collaborations and government grants linked to high-tech projects (National Torch Program participation).

• Market position: Ranked among China's top 100 pharmaceutical enterprises and designated a key high-tech firm in the National Torch Program, supporting preferential policies and R&D incentives.
• Pipeline & growth drivers: Dermatology (Roflumilast Foam clinical start, 2025), improved margins from higher-value finished drugs, and expansion of contract manufacturing capacity.
• Risks: 2024 revenue decline and a ~26% one-year market cap drop reflect pricing pressure, competition and cyclical demand in the pharma sector.